(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 40.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.87%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.2%.
Tg Therapeutics's revenue in 2026 is $531,898,000.On average, 10 Wall Street analysts forecast TGTX's revenue for 2026 to be $145,023,583,299, with the lowest TGTX revenue forecast at $131,779,869,897, and the highest TGTX revenue forecast at $156,081,179,062. On average, 8 Wall Street analysts forecast TGTX's revenue for 2027 to be $184,637,241,513, with the lowest TGTX revenue forecast at $150,184,853,051, and the highest TGTX revenue forecast at $213,213,942,693.
In 2028, TGTX is forecast to generate $239,250,492,657 in revenue, with the lowest revenue forecast at $211,308,829,281 and the highest revenue forecast at $265,604,561,523.